Three cancer drugs separately earned FDA approval: The KRAS inhibitor sotorasib (Lumakras; Amgen) was approved for use with the EGFR inhibitor panitumumab (Vectibix; Amgen) to treat patients with ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
1Department of Biology, University of Rochester, Rochester, New York. Search for other works by this author on: 2Westlake Disease Modeling Lab, Westlake Laboratory of Life Sciences and Biomedicine, ...
1Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
3Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. *Corresponding Author: David A. Reardon, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
1Northwestern University, Chicago, Illinois.
Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee. *Corresponding Author: Brent A. Orr, Department of Pathology, St. Jude Children ...
1Division of Solid Tumor Oncology, Memorial Sloan Kettering, New York, New York. *Corresponding Author: Luis A. Diaz Jr, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. E ...
1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Search for other works by this author on: ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback